Model for End-Stage Liver Disease (MELD) and allocation of donor livers

被引:2198
|
作者
Wiesner, R
Edwards, E
Freeman, R
Harper, A
Kim, R
Kamath, P
Kremers, W
Lake, J
Howard, T
Merion, RM
Wolfe, RA
Krom, R
机构
[1] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA
[2] United Network Organ Sharing, Richmond, VA USA
[3] Tufts Univ New England Med Ctr, Boston, MA 02111 USA
[4] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA
[5] Suburban Surg Associates, St Louis, MO USA
[6] Sci Registry Transplant recipients, Ann Arbor, MI USA
关键词
D O I
10.1053/gast.2003.50016
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: A consensus has been reached that liver donor allocation should be based primarily on liver disease severity and that waiting time should not be a major determining factor. Our aim was to assess the capability of the Model for End-Stage Liver Disease (MELD) score to correctly rank potential liver recipients according to their severity of liver disease and mortality risk on the OPTN liver waiting list. Methods: The MELD model predicts liver disease severity based on serum creatinine, serum total bilirubin, and INR and has been shown to be useful in predicting mortality in patients with compensated and decompensated cirrhosis. In this study, we prospectively applied the MELD score to estimate 3-month mortality to 3437 adult liver transplant candidates with chronic liver disease who were added to the OPTN waiting list at 2A or 213 status between November, 1999, and December, 2001. Results: In this study cohort with chronic liver disease, 412 (12%) died during the 3-month follow-up period. Waiting list mortality increased directly in proportion to the listing MELD score. Patients having a MELD score <9 experienced a 1.9% mortality, whereas patients having a MELD score greater than or equal to40 had a mortality rate of 71.3%. Using the c-statistic with 3-month mortality as the end point, the area under the receiver operating characteristic (ROC) curve for the MELD score was 0.83 compared with 0.76 for the Child-Turcotte-Pugh (CTP) score (P < 0.001). Conclusions: These data suggest that the MELD score is able to accurately predict 3-month mortality among patients with chronic liver disease on the liver waiting list and can be applied for allocation of donor livers.
引用
收藏
页码:91 / 96
页数:6
相关论文
共 50 条
  • [21] Assignment of steatotic livers by the Mayo model for end-stage liver disease
    Briceño, J
    Padillo, J
    Rufián, S
    Solórzano, G
    Pera, C
    TRANSPLANT INTERNATIONAL, 2005, 18 (05) : 577 - 583
  • [22] THE IMPACT OF LISTING MODEL FOR END-STAGE LIVER DISEASE (MELD) SCORE ON LIVER TRANSPLANTATION
    Fox, Alyson N.
    Reddy, Rajender
    Guttenberg, Katie B.
    Forde, Kimberly A.
    Ellenberg, Susan
    Lewis, James D.
    HEPATOLOGY, 2010, 52 (04) : 664A - 664A
  • [23] Impact of the Model for End-Stage Liver Disease (MELD) Score on Liver Transplantation in Greece
    Karapanagiotou, A.
    Kydona, C.
    Dimitriadis, C.
    Papadopoulos, S.
    Theodoridou, T.
    Tholioti, T.
    Fouzas, G.
    Imvrios, G.
    Gritsi-Gerogianni, N.
    TRANSPLANTATION PROCEEDINGS, 2014, 46 (09) : 3212 - 3215
  • [24] Model for end-stage liver disease (MELD) exception for unusual metabolic liver diseases
    McDiarmid, Sue
    Gish, Robert G.
    Horslen, Simon
    Mazariegos, George V.
    LIVER TRANSPLANTATION, 2006, 12 (12) : S124 - S127
  • [25] Model for end-stage liver disease (MELD) exception for familial amyloidotic polyneuropathy
    Pomfret, Elizabeth
    Gish, Robert G.
    Brandhagen, David
    LIVER TRANSPLANTATION, 2006, 12 (12) : S100 - S101
  • [26] Model for end-stage liver disease (MELD) exception for hereditary hemorrhagic telangiectasia
    Garcia-Tsao, Guadalupe
    Gish, Robert G.
    Punch, Jeffrey
    LIVER TRANSPLANTATION, 2006, 12 (12) : S108 - S109
  • [27] Model for end-stage liver disease (MELD) exception for cholangiocarcinoma or biliary dysplasia
    Gores, Gregory J.
    Gish, Robert G.
    Sudan, Debra
    Rosen, Charles B.
    LIVER TRANSPLANTATION, 2006, 12 (12) : S95 - S97
  • [28] MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era
    Kim, W. Ray
    Mannalithara, Ajitha
    Heimbach, Julie K.
    Kamath, Patrick S.
    Asrani, Sumeet K.
    Biggins, Scott W.
    Wood, Nicholas L.
    Gentry, Sommer E.
    Kwong, Allison J.
    GASTROENTEROLOGY, 2021, 161 (06) : 1887 - +
  • [29] Improvements in the model for end-stage liver disease (MELD) severity score.
    Dykstra, DM
    Wiesner, RH
    Port, FK
    Wolfe, RA
    Merion, RM
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 516 - 516
  • [30] Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine
    Lau, Tsang
    Ahmad, Jawad
    HEPATIC MEDICINE-EVIDENCE AND RESEARCH, 2013, 5 : 1 - 10